# A Adaptive Design Clinical Trial to Evaluate the Efficacy and Safety of TDI01 Suspension in the Treatment of Idiopathic Pulmonary Fibrosis (IPF)

> **NCT07464912** · PHASE3 · RECRUITING · sponsor: **Beijing Tide Pharmaceutical Co., Ltd** · enrollment: 508 (estimated)

## Conditions studied

- Idiopathic Pulmonary Fibrosis (IPF)

## Interventions

- **DRUG:** TDI01

## Key facts

- **NCT ID:** NCT07464912
- **Lead sponsor:** Beijing Tide Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-24
- **Primary completion:** 2029-07-30
- **Final completion:** 2029-12-30
- **Target enrollment:** 508 (ESTIMATED)
- **Last updated:** 2026-03-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07464912

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07464912, "A Adaptive Design Clinical Trial to Evaluate the Efficacy and Safety of TDI01 Suspension in the Treatment of Idiopathic Pulmonary Fibrosis (IPF)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07464912. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*